Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Pemigatinib Monotherapy in Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
2016-002596-10Phase 2Unknown
- Sponsor
- Incyte
- Start
- Jan 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemigatinib in Myeloid/lymphoid neoplasm with fibroblast growth factor receptor 1 rearrangement (MLN-FGFR1), sponsored by Incyte. Primary endpoint: Complete remission rate. Status: unknown.
02
Drugs
pemigatinib
03
Conditions
Myeloid/lymphoid neoplasm with fibroblast growth factor receptor 1 rearrangement (MLN-FGFR1)
Beyond the preview
Go deeper on 2016-002596-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002596-10.